(dolutegravir sodium + lamivudine)
Marketedupdated 2mo agoby ViiV Healthcare Company
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
News(0)
no news has mentioned this drug yet
nothing on the calendar yet
no news has mentioned this drug yet
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
comments(0)
5-min edit window · permanent after that